James HesterHikma Pharmaceuticals has struck a licensing agreement with South Korea biopharmaceutical name Celltrion to distribute and market its cancer treatment Truxima in the Middle East and North Africa.
Truxima is used to treat patients with non-Hodgkin's lymphoma, chronic lymphocytic leukemia as well as rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis.
Exclusive agreements
The deal means London-listed Hikma now has exclusive agreements with Celltrion for three biosimilar products - Truxima, Remsima and Herzuma - in all its Middle East and North African markets (MENA).
“Global partnerships are an integral part of our strategy to enhance our portfolio in key therapeutic areas and increase patients' access to high-quality, affordable medicines," said Mazen Darwazah, vice chairman and chief executive officer of MENA and emerging markets at Hikma.